Skip to main content
SpringerLink
Log in

Aktuelle Aspekte der psychopharmakotherapeutischen Depressionsbehandlung

  • Conference paper
Spektrum psychiatrischer Arbeit

  • 52 Accesses

Zusammenfassung

Seit der Einführung von Imipramin in den späten 50er Jahren (Kuhn, 1957) wurde eine ganze Reihe von Antidepressiva entwickelt, die sich hinsichtlich ihrer Struktur, ihren pharmakokinetischen Eigenschaften und ihren neurochemischen Wirkungen unterscheiden. Heute stehen mehr als acht Klassen von Antidepressiva zur Verfügung und trotz der immens gewachsenen Therapiemöglichkeiten oder vielleicht deshalb scheint die Behandlung depressiver Störungen komplizierter geworden zu sein. Die Durchführung einer differenzierten pharmakotherapeutischen Depressionsbehandlung bedarf mehr denn je einer umfassenden Kenntnis über die Eigenschaften der zur Verfügung stehenden Psychopharmaka, insbesondere der neu zugelassenen antidepressiven Substanzen. Im folgenden soll nun ein Öberblick der neu entwickelten Antidepressiva gegeben werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Anderson IM, Tomenson BM (1994) The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 8: 238–249.

    Article  CAS  Google Scholar 

  • Baldwin DS, Hawley CJ, Abed RT, Maragakis BP, Cox J, Buckingham SA, Pover GH, Ascher A (1996) A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 57 [Suppl 2]:46–52

    PubMed  CAS  Google Scholar 

  • Bech P, Cialdella P (1992) Citalopram in depression-meta-analysis of intended and unintended effects. Int Clin Psychopharmacol 6 [Suppl 5]: 45–54

    Article  PubMed  Google Scholar 

  • Berzewski H, Van Moffaert M, Gagiano CA (1997) Efficaca and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 7 [Suppl 1]: 37–47

    Article  Google Scholar 

  • Boyer WF, Feighner JP (1992) An overview of paroxetine. J Clin Psychiatry 53 [Suppl 2]: 3–6

    PubMed  Google Scholar 

  • Cohn JB, Wilcox C (1985) A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 46: 26–31

    PubMed  CAS  Google Scholar 

  • Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, Small JG (1995) Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 38: 592–602

    Article  PubMed  CAS  Google Scholar 

  • Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS (1996) Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 57 [Suppl 2]: 53–62

    PubMed  CAS  Google Scholar 

  • Feighner JP (1994) The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 55: 62–68

    PubMed  Google Scholar 

  • Feighner JP, Boyer WF, Meredith CH, Hendrickson G (1989) A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 4: 239–244

    Article  PubMed  CAS  Google Scholar 

  • Gardier AM, Malagié I, Trillat AC, Jacquot C, Artigas F (1996) Role of 5-HT1a autoreceptors in the mechanism of action of serotonergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam Clin Pharmacol 10: 16–27

    Article  PubMed  CAS  Google Scholar 

  • Goodwin GM, Edin FR (1996) How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry 57 [Suppl 4]: 9–13

    PubMed  CAS  Google Scholar 

  • Hall J (1988) Fluoxetine: efficacy against placebo and by dose — an overview. Br J Psychiatry 153 [Suppl 3]: 59–63

    Google Scholar 

  • Hegerl U, Bottlender R, Gallinat J, Kuss HJ, Ackenheil M, Möller HJ (1998) The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci 248: 96–103

    Article  PubMed  CAS  Google Scholar 

  • Heiligenstein JH, Tollefson GD, Faries DE (1994) Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo. J Affect Disord 30: 163–173

    Article  PubMed  CAS  Google Scholar 

  • Kasper S (1995) Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol 10 [Suppl 4]: 25–35

    Article  PubMed  Google Scholar 

  • Kasper S, Möller HJ (1995) Antidepressive Psychopharmakotherapie. Dtsch Ärzteblatt 92: 428–434

    Google Scholar 

  • Kasper S, Pletan Y, Solles A, Tournoux A (1996) Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol 11 [Suppl 4]: 35–39

    Article  PubMed  Google Scholar 

  • Kelsey JE (1996) Dose-response relationship with venlafaxine. J Clin Psvchopharmacol 16 [Suppl 2]: 21–28

    Article  Google Scholar 

  • Lane R, Baldwin D, Preskorn S (1995) The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 9: 163–178

    CAS  Google Scholar 

  • Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF (1996) Milnacipran and selective reuptake inhibitors in major depression. Int Clin Psychopharmacol 11 [Suppl 4]: 41–46

    Article  PubMed  Google Scholar 

  • Marcus RN, Mendels J (1996) Nefazodone in the treatment of severe, melancholic, and recurrent depression. J Clin Psychiaty 57: 19–23

    CAS  Google Scholar 

  • Montgomery SA (1995) Safety of mirtazapine: a review. Int Clin Psychopharmacol 10 [Suppl 4]:37–45

    Article  PubMed  Google Scholar 

  • Montgomery SA (1997) Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 11 [Suppl 4]: 9–15

    Google Scholar 

  • Montgomery SA, Djärv L (1996) The antidepressant efficacy of Citalopram. Int Clin Psychopharmacol 11 [Suppl 1]: 29–33

    Article  PubMed  Google Scholar 

  • Montgomery SA, Henry JA, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D, (1994) Selective serotonin reuptake inhibitors-meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9: 47–53

    Article  PubMed  CAS  Google Scholar 

  • Mucci M (1997) Reboxetine: a review of antidepressant tolerabilty. J Psychopharmacol 11 [Suppl 4]: 33–37

    Google Scholar 

  • Puech A, Montgomery SA, Prost JF, Solles A, Briley M (1997) Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12: 99–108

    Article  PubMed  CAS  Google Scholar 

  • Riva M, Brunello N, Rovescalli AC, Galimberti R, Carfagna N, Carminati P, Pozzi O, Ricciardi S, Roncucci R, Rossi A, Racagni G (1989) Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J Drug Dev 1: 243–253

    Google Scholar 

  • Robinson DS, Roberts DL, Smith JM, Stringfellow JC, Kaplita SB, Seminara JA, Marcus RN (1996) The safety profile of nefazodone. J Clin Psychiatry 57 [Suppl 2]: 31–38

    PubMed  CAS  Google Scholar 

  • Rudolph RL, Derivan AT (1996) The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 16 [Suppl 2]: 54–61

    Article  Google Scholar 

  • Stark P, Hardison CD (1985) A review of multicenter controlled studies of fluoxetine vs. Imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 46: 53–58

    PubMed  CAS  Google Scholar 

  • Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148: 705–713

    PubMed  CAS  Google Scholar 

  • Tignol J, Stoker MJ, Dunbar GC (1992) Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 7: 91–94

    PubMed  CAS  Google Scholar 

  • Ware MR (1997) Fluvoxamine: a review of the controlled trials in depression. J Clin Psychiatry 58 [Suppl 5]: 15–23

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. P. Mavrogiorgou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. Hegerl
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Psychiatrie und Psychotherapie, Klinikum Erfurt, Nordhäuser Straße 74, D-99089, Erfurt, Bundesrepublik Deutschland

    Konrad Peter

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag/Wien

About this paper

Cite this paper

Mavrogiorgou, P., Hegerl, U. (2000). Aktuelle Aspekte der psychopharmakotherapeutischen Depressionsbehandlung. In: Peter, K. (eds) Spektrum psychiatrischer Arbeit. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6768-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6768-7_12

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-83402-2

  • Online ISBN: 978-3-7091-6768-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation